Thymosin Alpha-1
Last reviewed September 26, 2026
Thymosin Alpha-1 is a peptide originally isolated from thymic tissue. Research examines its role in the maturation of T-cells and in coordinating a balanced immune response.
Mechanism of action
Research investigates Thymosin Alpha-1 for activity at toll-like receptors on dendritic cells, upstream of the T-cell differentiation it is most associated with.
- T-Cell MaturationStudied for its influence on the development and differentiation of T-cells within adaptive immunity.
- Receptor SignalingExplored for activity at toll-like receptors that sit early in the immune recognition cascade.
- Route studied
- Subcutaneous
- Research status
- Early clinical
Thymosin Alpha-1 has been examined in human research, including a multicenter cohort study in COVID-19 and clinical work in chronic hepatitis B, alongside animal and cell studies of its immune effects.
What the research covers
What research examines
- T-cell maturation and differentiation
- Toll-like receptor signaling on dendritic cells
- NK-cell activity in immunosuppressed mouse models
- Chronic hepatitis B research
- COVID-19 in a multicenter cohort study
- Immunoregulation in cancer and immuno-oncology research
Reported effects in studies
- Human safety data in the cited literature are limited
- Adverse events are not summarized in the cited studies
- A 1996 laboratory study reported that Thymosin Alpha-1 did not promote growth or oncogenic transformation
- Cell studies reported no effect on F508del-CFTR maturation or activity
What research protocols have used
Research protocols have used 1.5–3 mg per administration, 3 times per week (morning), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorCited research
- Thymosin alpha-1.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2001 · Review · PubMed 11381492
- Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
Frontiers in immunology · 2021 · PubMed 34408744
- Thymosin alpha-1 treatment in chronic hepatitis B.
Expert opinion on biological therapy · 2015 · PubMed 25640173
- Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.
Cancer immunology, immunotherapy : CII · 1983 · PubMed 6553515
- Thymosin alpha 1 does not promote growth or oncogenic transformation.
International journal of immunopharmacology · 1996 · PubMed 8933211
Questions about Thymosin Alpha-1
Thymosin Alpha-1 is a peptide originally isolated from thymic tissue. Research has examined its role in the maturation of T-cells and in coordinating a balanced immune response. It is broadly associated with immune signaling and has been studied for effects on both T-lymphocytes and natural killer (NK) cells. It has been the subject of reviews, animal studies, and human research spanning several decades.
Research investigates Thymosin Alpha-1 for activity at toll-like receptors on dendritic cells, which sit early in the immune recognition cascade. This upstream signaling is thought to relate to the T-cell differentiation it is most associated with. It has also been studied for its influence on the development and differentiation of T-cells within adaptive immunity. The full mechanism remains an active area of investigation.
Research has covered several areas. A 1983 mouse study reported restored NK-cell activity and reduced tumor progression in animals immunosuppressed by cytostatics or X-rays. Human research includes chronic hepatitis B and a multicenter cohort study in COVID-19. Reviews have discussed its immunoregulatory potential in cancer and immuno-oncology, and its relationship to aging. Cystic fibrosis cell studies reported no correction of F508del-CFTR.
Human safety data in the cited literature are limited, and adverse events are not summarized in the cited studies. A 1996 laboratory study reported that Thymosin Alpha-1 did not promote growth or oncogenic transformation. Separate cell studies found it did not influence F508del-CFTR maturation or activity, which is a negative efficacy finding rather than a safety signal. Further controlled research would be needed to characterize its safety profile fully.
Research protocols have used 1.5–3 mg per administration by the subcutaneous route, 3 times per week in the morning, in 8-week blocks followed by 4 weeks off. These figures describe what has appeared in research protocols and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. CoreX supplies Thymosin Alpha-1 for laboratory research use only.
Ask about Thymosin Alpha-1
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
Thymosin Alpha-1 at CoreX
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Foundation
$109.00









